Effect of a Nutraceutical Combination on Oxidative Stress Biomarkers in Healthy Subjects and Patients with Alzheimer's Disease.
Background/Objectives: Advanced glycation end products (AGEs) and oxidative stress increase with aging and are implicated in Alzheimer's disease (AD). We developed an anti-glycation blend using LC-MS-based screening and assessed its effects on oxidative and glycation-related biomarkers in humans. Me...
| Publicado en: | Nutrients Vol. 18; no. 5; pp. 789 - 802 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
MDPI
Mar2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192640401&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192640401 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726643 B0TT jtl: Nutrients issn: 20726643 maglogo: N pubinfo: dt: Mar2026 vid: 18 iid: 5 pid: 97109 pub: MDPI artinfo: ui: 192640401 192640401 192640401 10.3390/nu18050789 192640401 ppf: 789 ppct: 13 formats: tig: atl: Effect of a Nutraceutical Combination on Oxidative Stress Biomarkers in Healthy Subjects and Patients with Alzheimer's Disease. aug: au: Jastrząb, Rafał Małecki, Andrzej Kmiecik-Małecka, Elżbieta Gorzkowska, Agnieszka Kubas, Kamil Widłak-Kargul, Justyna Wolman, Damian Matkiewicz, Katarzyna Nowacka-Chmielewska, Marta Liśkiewicz, Daniela Grabowska, Konstancja Grabowski, Mateusz Pondel, Natalia Początek, Gabriela Kłodowska, Gabriela Mytych, Jennifer affil: Research and Development Center, Olimp Laboratories Sp. z o.o. 39-200 Dębica, Poland sug: subj: Alzheimer's Disease Diet Therapy Functional Food Therapeutic Use Oxidative Stress Evaluation Biological Markers Treatment Outcomes Dietary Supplements Glycation End Products, Advanced Aging Funding Source Human Male Female Aged Aged, 80 and Over Descriptive Statistics Randomized Controlled Trials Random Assignment Liquid Chromatography-Mass Spectrometry Double-Blind Studies Analysis of Variance Post Hoc Analysis Prospective Studies Enzyme-Linked Immunosorbent Assay Data Analysis Software Colorimetry Aged: 65+ years Aged, 80 & over Male Female ab: Background/Objectives: Advanced glycation end products (AGEs) and oxidative stress increase with aging and are implicated in Alzheimer's disease (AD). We developed an anti-glycation blend using LC-MS-based screening and assessed its effects on oxidative and glycation-related biomarkers in humans. Methods: Twelve candidate compounds were screened in a BSA–glucose model using LC-MS peptide mapping to quantify lysine glycation and rank inhibitory activity. The top candidates were combined into a three-compound blend (quercetin, rutin, genistein). In a randomized, double-blind, placebo-controlled 3-month trial, older healthy adults (n = 30) and individuals with AD (n = 30) received anti-AGE blend (n = 15 in older group and n = 15 in AD group) or placebo (n = 15 in older group and n = 15 in AD group). Serum malondialdehyde and urinary Nε-(carboxymethyl)lysine were measured pre–post intervention. Pre/post and between-arm comparisons within each population were performed using REML ANOVA with Tukey post hoc tests. Serum MDA (malondialdehyde) and urinary CML (Nε-(carboxymethyl)lysine) were prespecified biomarker outcomes and are reported here as co-primary biomarker endpoints. No formal a priori sample size calculation was performed; the study size was feasibility-based. Results: LC-MS screening identified genistein, quercetin, and rutin as the most consistent inhibitors of glucose-driven BSA glycation. In older healthy adults, serum MDA decreased after anti-AGE supplementation (p < 0.001) and differed from the placebo (p < 0.01), while no change was observed within the placebo group (ns). In the AD cohort, MDA did not change significantly from baseline within either arm (ns), but post-intervention MDA was lower in anti-AGE than in the placebo (p < 0.05). Urinary CML was unchanged in older healthy adults (ns in both arms), whereas in AD, it decreased after anti-AGE supplementation (p < 0.01) and differed from the placebo (p < 0.05). Conclusions: A screening-guided anti-glycation blend supplementation was associated with changes in selected biomarkers in humans: MDA decreased across cohorts, while CML decreased selectively in AD. Larger trials with extended biomarker panels and LC–MS/MS confirmation are warranted. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|